Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  gamma-secretase/Notch signalling pathway inhibitor RO4929097
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-19 of 19 for your search:
Start Over
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01412, CDR0000680558, MSKCC-10049, 10-049, 8406, N01CM62206, P30CA008748, U01CA069856, NCT01154452
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02509, CDR0000683099, ABTC-1002, U01CA137443, NCT01189240
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02524, CDR0000684220, 10-085, 8491, N01CM62206, P30CA008748, U01CA069856, MSKCC-10085, NCT01196416
An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NP22383, 2008-006384-37, NCT01070927
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02040, SWOG-S0933, CDR0000671815, S0933, U10CA032102, NCT01120275
RO4929097 in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02845, MCC 16221, 8537, N01CM62208, P30CA076292, NCT01116687
A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03068, PHL-077, 8563, N01CM00032, NCT01141569
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03069, PHL-079, 8635, N01CM00032, N01CM00038, N01CM00071, N01CM62201, N01CM62203, N01CM62209, PMH-PHL-079, NCT01175343
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02537, CDR0000687335, 10-0273, 8490, U01CA070095, P30CA046934, UCHSC-10-0273, NCT01232829
A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NO21321, NCT00532090
Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01550, CDR0000666959, PMH-PJC-003, PJC-003, 8501, U01CA132123, NCT01096355
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2011-01410, CDR0000672641, 09-177, 8556, P30CA008748, U01CA069856, MSKCC-09177, NCT01119599
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01428, CDR0000673867, PJC-004, 8503, U01CA132123, CAN-OCI-PJC-004, NCT01131234
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01433, CDR0000674950, PHL-078, 8575, U01CA132123, PMH-PHL-078, NCT01145456
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02918, CDR0000680610, CO09907, 8515, U01CA062491, U01CA132123, P30CA014520, WCCC-CO09907, NCT01158274
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-01975, 2009-0769, 8508, N01CM00039, N01CM62202, P30CA016672, U01CA062461, MDA-2009-0769, NCT01193881
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02529, 8500, CDR0000684714, PJC-005, U01CA132123, PMH-PJC-005, NCT01198184
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02916, CDR0000685426, CO09908, 8516, P30CA014520, U01CA062491, WCCC-CO-09908, NCT01218620
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-03813, CDR0000687152, OSU-OH007, 2010C0043, OSU 10011, 8518, P30CA016058, U01CA076576, OH007, NCT01238133
Start Over